The increasing number of treatment options and the high costs associated with epilepsy have fostered the development of economic evaluations in epilepsy. It is important to examine the availability and quality of these economic evaluations and to identify potential research gaps. As well as looking at both pharmacologic (antiepileptic drugs [AEDs]) and nonpharmacologic (e.g., epilepsy surgery, ketogenic diet, vagus nerve stimulation) therapies, this review examines the methodologic quality of the full economic evaluations included. Literature search was performed in MEDLINE, EMBASE, NHS Economic Evaluation Database (NHS EED), Econlit, Web of Science, and CEA Registry. In addition, Cochrane Reviews, Cochrane DARE and Cochrane Health Technology Assessment Databases were used. To identify relevant studies, predefined clinical search strategies were combined with a search filter designed to identify health economic studies. Specific search strategies were devised for the following topics: (1) AEDs, (2) patients with cognitive deficits, (3) elderly patients, (4) epilepsy surgery, (5) ketogenic diet, (6) vagus nerve stimulation, and (7) treatment of (non)convulsive status epilepticus. A total of 40 publications were included in this review, 29 (73%) of which were articles about pharmacologic interventions. Mean quality score of all articles on the Consensus Health Economic Criteria (CHEC)-extended was 81.8%, the lowest quality score being 21.05%, whereas five studies had a score of 100%. Looking at the Consolidated Health Economic Evaluation Reporting Standards (CHEERS), the average quality score was 77.0%, the lowest being 22.7%, and four studies rated as 100%. There was a substantial difference in methodology in all included articles, which hampered the attempt to combine information meaningfully. Overall, the methodologic quality was acceptable; however, some studies performed significantly worse than others. The heterogeneity between the studies stresses the need to define a reference case (e.g., how should an economic evaluation within epilepsy be performed) and to derive consensus on what constitutes "standard optimal care."
• Forty publications were included in this review, 29 (73%) of which were articles about pharmacologic interventions or AEDs
• Overall, the methodologic quality of the studies was acceptable; however, some studies performed significantly worse than others
• Articles differed substantially in methodology hampering the attempt to combine the information regarding various interventions in a meaningful way
• The heterogeneity between the studies stresses the need to define a reference case and to derive consensus on what constitutes "standard optimal care"
• The number of economic evaluations in certain areas, such as vulnerable groups, appears to be limited. Future research should aim to identify and fill knowledge gaps in specific areas within the field of epilepsy and economic evaluations Epilepsy is a chronic neurologic disorder of the brain that involves recurrent seizures as a result of sudden excessive electrical discharges in a group of brain cells. The site of such discharges determines the clinical manifestation. Hence, clinical manifestations of seizures vary, depending on where the disturbance starts and how far it spreads. Epilepsy is the most common serious neurologic disorder, with a global prevalence of almost 60 million 1 and an annual incidence of 50.4 per 100,000 persons. 2 The increasing number of treatment options and the high costs associated with epilepsy have fostered the development of economic evaluations in this field. Economic evaluations compare costs and consequences of health care interventions: for example, by examining the added value (in both costs and effects) of antiepileptic drugs (AEDs) or electric stimulation such as the vagus nerve stimulation (VNS) or deep brain stimulation (DBS).
The goal of good health policy making is to achieve health benefits and therefore to "produce" health. In order to make good choices in health care, policy makers try to find a balance between costs and effects of interventions. Economic evaluations provide a solution for this assessment, as they provide information about the relative efficiency of choosing between alternative interventions. In a "full" economic evaluation, the additional benefits of a health care program are weighed against the additional costs compared to a reference program. For example, an economic evaluation will reveal whether a new AED is "good value for money" compared to existing alternatives. Economic evaluations are important at different levels of decision making. An increasing number of countries are using cost-effectiveness as a criterion for deciding whether an intervention, especially pharmaceuticals, should be reimbursed. 3 Hence, in some countries, economic assessments are now of such high importance that the cost of a drug will not be reimbursed if no economic evaluation has been conducted. But also at the level of national health care services or at the level of the individual patient, economic evaluations can help in decision making. The principle of economic evaluation is simple: determine the cost-benefit ratio and select the intervention for which this ratio is the lowest. Conducting a high-quality full economic evaluation is, however, not easy.
The aim of this review is to present an overview of published full economic evaluations of all health care interventions for patients with epilepsy. The treatments assessed in this review will be categorized according to the topics covered in the clinical practice guidelines (CPGs) as developed by the International League Against Epilepsy (ILAE) and the National Institute for Care Excellence (NICE) for treatment of epilepsy. 4, 5 This review looks at both pharmacologic (i.e., AEDs) and nonpharmacologic therapies (e.g., epilepsy surgery, ketogenic diet, and VNS) and devotes a specific section to vulnerable groups (i.e., elderly and children). In addition, it includes both trial-based and model-based full economic evaluations. Furthermore, the methodologic quality will be determined of published full economic evaluations of all health care interventions for patients with epilepsy.
Essentials of economic evaluations
The general approach of an economic evaluation is to compare the consequences of health care programs with their costs. The term "full EE" refers to the comparative analysis of alternative courses of action in terms of both costs (resource use) and consequences (outcomes, effects). 6 An incremental cost-effectiveness ratio (ICER) is then calculated for each treatment being assessed, where the denominator reflects the incremental gain in effects, benefits, or utilities, and the numerator reflects the additional cost of achieving that health gain.
Types of economic evaluations
There are four types of full economic evaluations, namely: cost-minimization analysis (CMA), cost-benefit analysis (CBA), cost-effectiveness analysis (CEA), and cost-utility analysis (CUA). 6 In CMA, the effects of the interventions of interest are assumed to be equal; one is, therefore, interested in a reduction in costs only. However, in cases where studies assume equal effectiveness without examining it, it is questionable whether one can speak of a full EE. In a CBA, attempts are made to place a value on the consequences of programs in monetary terms, in order to make them commensurate with the costs. Potentially, this is the broadest program for justifying the costs. Expressing benefits in monetary terms is, however, often hampered by measurement problems. In a CEA, the consequences of programs are measured in terms of the appropriate natural effects of physical units, such as "50% seizure reduction" or "seizure-free patients." The main argument for these clinical measures is the relative ease of measurement and interpretation. One of the major limitations of the CEA and its disease-specific outcome is that it does not permit comparisons with interventions evaluated in other disease areas (e.g., comparing blood pressure in hypertension treatment and seizure frequency in epilepsy treatment). In a CUA, the consequences of programs are adjusted by health state preference scores or utility weights; that is, states of health associated with the outcomes are valued relative to one another. The most common measure of consequences in a CUA is the qualityadjusted life-year (QALY). 6 A QALY incorporates effects in terms of both quality of life (utilities) and survival (lifeyears gained). In contrast to the outcome measure of the CEA, it is a generic outcome measure. To calculate QALYs, it is necessary to represent health on a scale where death and full health are assigned values of 0 and 1, respectively. Because there are many ways of obtaining utilities to calculate QALYs, it is important to look at the methods used or the questionnaire chosen. A disease-specific quality of life measure, for example, is specific to an individual disease or condition and includes dimensions relevant to that disease (e.g., epilepsy-specific QOL measure: QOLIE-89). A generic quality of life measure is a comprehensive measure of health that has a broad range of components and is applicable across different patient groups (e.g. EuroQoL). 7 Alternatively, other generic outcome measures are sometimes used such as disability adjusted life years (DALYs). DALYs represent the number of years lost due to ill health, disability, or early death.
Study design
There are two study designs for conducting an economic evaluation, namely trial-based or model-based design. In trial-based economic evaluations, data on resource use and effectiveness are collected simultaneously, for example, alongside a randomized trial. The benefits of this approach are that results reflect actual data from real patients, and the internal validity of the data can be assessed through controlled clinical conditions. A disadvantage is that it may not be possible to generalize the treatment pathways and patient samples to the larger population. To overcome this disadvantage, it is possible to model the costs and outcomes of different treatments. Model-based economic evaluations provide a means of bringing all clinical, costs, and quality of life data together in one model by using techniques of epidemiology or decision analysis. The results can, therefore, be generalized in terms of the larger population. Lifetime costs and outcomes can then be estimated.
Perspective of analysis
The perspective indicates from which point of view an economic evaluation is being considered and determines which costs will be examined, and thus which conclusions can be drawn from any particular economic evaluation. A program that looks unattractive from one viewpoint may look significantly better when other viewpoints are considered. Analytical viewpoints may include any or all of the following: the individual patient, the specific institution, the target group for specific services, the Ministry of Health budget, and the community or societal viewpoint. According to the majority of national guidelines, an economic evaluation study has to be performed from the societal perspective. 6, 8 In this case, all costs, including health care costs, costs of patient and family, and costs in other sectors should be measured, irrespective of who benefits from them or who pays for them.
Methods
A protocol of this systematic review was published in the International Prospective Register of Systematic Reviews (http://www.crd.york.ac.uk/prospero/; registration number CRD42015019278). The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement was followed in the reporting of this article. 9 
Literature search
A literature search was performed in MEDLINE (via PubMed), EMBASE, NHS Economic Evaluation Database (NHS EED), Econlit, Web of Science, and CEA Registry. In addition, Cochrane Reviews, Cochrane DARE, and Cochrane Health Technology Assessment Databases were used. To identify relevant studies, we combined predefined clinical search strategies (to assess effectiveness of treatments) with a search filter constructed by the health information research unit of McMaster University (see: http:// hiru.mcmaster.ca/hiru/HIRU_Hedges_EMBASE_Strategie s.aspx), which is designed to identify health economic studies. In addition, citation tracking was performed for all included studies.
As this review focuses on topics discussed in the CPGs, as developed by the ILAE and NICE for treatment of epilepsy, specific search strategies were devised for the following topics: (1) AEDs; (2) patients with cognitive deficits; (3) elderly patients; (4) epilepsy surgery; (5) ketogenic diet; (6) VNS; (7) treatment of (non)convulsive status epilepticus in children; and (8) treatment of (non)convulsive status epilepticus in adults.
To examine each subject/subarea, some "key" references were identified beforehand that had to be identified through the various search strategies in the various databases. The search strategy can be found in Appendix S1.
Inclusion/exclusion criteria
The review focused on full economic evaluations comparing different treatment options for patients with epilepsy. In addition, only articles published in English during the period January 2000-March 2016 were considered. Excluded were those papers focusing on diagnostics.
Data extraction and quality assessment
Two researchers selected the abstracts and extracted the data independently of each other. Data were extracted using a predefined form that included the following information: study type, year of publication, year of currency and currency type, study setting (country), target population (gender and age), analysis perspective, intervention type, health outcome measure, and type of economic evaluation.
To determine the quality of the studies, the Consensus on health economics checklist extended (CHEC-extended) was used. This is an extension of the original Consensus Health Economic Criteria (CHEC) checklist to include questions about model-based economic evaluations. 10, 11 To determine the quality of reporting of the included studies, the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement was used. 12 To limit the possibility of biased results, two reviewers independently reviewed both the data extraction form and the quality appraisal of the included studies (BFMW and OG). As a consequence, all the articles were doublescored on the data extraction and quality assessment part. Possible differences in scoring were discussed until consensus was reached. Both checklists can be found in Appendix S2.
To calculate an overall quality score for each article based on the CHEC checklist, each time a "Yes" was scored, 1 point was allocated and each time "suboptimal" was scored, 0.5 points were allocated. The total score per article was then divided by all the applicable items for that particular study. 11 The same calculation was applied for the CHEERS, the only exception being, there is no "suboptimal" in the CHEERS.
All costs were converted to Euros (€) and applied to the year 2015 based on estimates from the International Monetary Fund (IMF) World Economic Outlook Database "GDP deflator index" (gross domestic product) dataset. This dataset contains "Gross Domestic Product Deflator values" for 184 countries (currencies) from 1980 onward. 13 
Results

Search results
A total of 1,474 publications were identified using the different search strategies and after removal of all duplicate studies; 1,028 publications were eligible for title and abstract screening. After screening the titles and abstracts for inclusion criteria, 959 articles were excluded. Next, 71
full-text articles were assessed for eligibility, 31 of which were excluded for various reasons: (1) no original research/ not a full report (n = 15); (2) no full economic evaluation (n = 9); (3) no epilepsy (n = 4); (4) only focused on diagnostics (n = 3). A total of 38 publications were finally included in this review. The flow chart of the literature search is presented in Figure 1 .
General characteristics
The most recent study was from 2016, and the oldest was published in 2000. Most studies were conducted in the United Kingdom (n = 12; 30%) followed by the Netherlands (n = 6; 15%). The included studies reported costeffectiveness for the following interventions: different types of AED (29 studies; 73%), ketogenic diet (2 studies; 5%), surgery in patients with refractory epilepsy (3 studies; 8%, self-management (3 studies; 8%), VNS (2 studies; 5%) and lastly drug monitoring in patients with epilepsy (1 study; 3%).
The most commonly used perspective was the health care perspective (67%), followed by the societal perspective (10%). In 28 (70%) of the 40 studies, a model was used to estimate costs and effects. A comprehensive list of all included studies can be found in Table 1 . Quality of the identified studies Mean quality score of all articles on the CHEC-extended was 81.8%, the lowest being 21.05%, whereas five studies had a score of 100% (see Table 2 ). Furthermore, pharmacologic studies scored 81.6% on average and nonpharmacologic studies scored 82.4% on average. Looking at the CHEERS, the average quality score was 77.0%, the lowest being 22.7%, and four studies rated as 100% (see Table 3 ). Furthermore, pharmacologic studies scored 77.4% on average and nonpharmacologic studies scored 75.5% on average. Hence, pharmacologic studies scored slightly better on the reporting of their study.
Pharmacologic interventions
Twenty-nine articles (73%) on pharmacologic interventions or AED were included in the study. Main outcomes and incremental cost-effectiveness ratios (ICERs)/incremental costutility ratios (ICURs) of all studies can be found in Table 4 .
AED as monotherapy
Knoester et al. 14 compared six different strategies encompassing carbamazepine, valproic acid, and lamotrigine: (1-2) carbamazepine as first-line monotherapy followed by either valproic acid or lamotrigine in the case of carbamazepine failing because of either a lack of seizure control or adverse effects; (3-4) valproic acid as first-line monotherapy followed by either carbamazepine or lamotrigine if valproic acid fails because of either a lack of seizure control or adverse effects; and (5-6) lamotrigine as first-line monotherapy followed by either carbamazepine or valproic acid if lamotrigine fails because of either a lack of seizure control or adverse effects. Using carbamazepine-valproic acid as a reference, the study concludes that this dominates valproic acid-carbamazepine, valproic acid-lamotrigine, and lamotrigine-carbamazepine; the ICER of carbamazepine-lamotrigine is €7,308 per complete success, and the ICER of lamotrigine-valproic acid, €48,593 per complete success.
One study compared lamotrigine with topiramate. 15 With regard to the ICER, it concluded that topiramate would dominate lamotrigine at current acquisition costs. Another study compared topiramate with lamotrigine and carbamazepine in patients with partial epilepsy, and with valproate and lamotrigine in patients with generalized epilepsy. 16 In patients with partial epilepsy, first-line topiramate and second-line carbamazepine resulted in an ICUR of €65,961 per QALY gained, compared to first-line carbamazepine and second-line topiramate; first-line carbamazepine and second-line topiramate dominated all other combinations. In patients with generalized epilepsy, topiramate followed by lamotrigine resulted in an ICUR of €3,043 per QALY gained, compared to valproate followed by lamotrigine; and topiramate followed by lamotrigine resulted in an ICUR of €11,445 per QALY gained, compared to valproate followed by topiramate.
Marson et al. 17 carried out two separate comparisons to examine the longer-term outcomes of standard versus new AED. In the first comparison, they compared carbamazepine, gabapentin, lamotrigine, oxcarbazepine, and topiramate. Topiramate and gabapentin were dominated by oxcarbazepine and lamotrigine. The ICUR for oxcarbazepine relative to carbamazepine was €9,788 per QALY gained. In the second comparison, they compared valproate, lamotrigine, and topiramate and found that lamotrigine was dominated by topiramate and that the ICUR of topiramate compared to valproate was €1,746 per QALY gained.
Balabanov et al. 18 have compared oxcarbazepine with carbamazepine but calculated only cost-effectiveness ratios (CERs). The CERs of carbamazepine (two different brands) were €911 and €1,153 per QALY gained, and the CER of oxcarbazepine was €2,761 per QALY gained. In another study, Balabanov et al. 19 compared patients on monotherapy with carbamazepine and valproate but did not calculate ICERs.
Finally, Chisholm et al. 20 compared the use of phenobarbitone, phenytoin, carbamazepine, and valproic acid to no treatment in nine developing regions across the world and concluded that the most cost-effective technology is first-line treatment in primary care with older AEDs such as phenobarbitone and phenytoin, because their expected population-level impact is similar to those of other first-line AEDs yet their acquisition costs are appreciably lower. In addition, two studies examined the cost-effectiveness of older versus newer AEDs in developing countries. Chisholm et al. 21 concluded that for sub-Saharan Africa and Southeast Asia, older AEDs dominated newer AEDs in primary care both at 50% or 80% coverage. Likewise, albeit not calculating incremental costs and effects, Gureje et al. 22 concluded that older AEDs in primary care implemented at 80% coverage offer the best value, as more DALYs were averted at a minimal increase in cost per DALY saved.
AED as add-on treatment
Most add-on AEDs were compared to standard therapy, other add-on AEDs, or placebo. Two articles compared lacosamide add-on with standard therapy and calculated an ICUR. Bolin et al. 23 found an ICUR of €30,409 per QALY gained, and Simoens et al. 24 demonstrated that standard AED therapy plus lacosamide dominated standard AED therapy. Another article compared lamotrigine add-on with standard therapy and calculated an ICER of €1,114 per patient with 50% or more seizure reduction. 25 There was one article comparing pregabalin add-on with standard therapy, calculating an ICUR of €50,193 per QALY and an ICER of €27 per seizure-free day. 26 Maltoni and Messori 27 compared topiramate add-on with standard therapy, calculating an ICUR of €36,831 per QALY gained (24); and Remak et al. 28 compared topiramate add-on with clobazam, gabapentin, lamotrigine, and vigabatrin. They calculated an ICUR of €13,246 per QALY gained for topiramate compared with vigabatrin (vigabatrin dominated gabapentin, lamotrigine, and clobazam).
Hawkins et al. 29 compared topiramate for generalized seizures with placebo add-on and calculated an ICUR of €57,935 per QALY gained. Furthermore, they compared different AEDs with placebo add-on for partial seizures and calculated an ICUR for oxcarbazepine of €28,776 per QALY gained (gabapentin, lamotrigine, tiagabine, leviteracetam, and topiramate were dominated by oxcarbazepine). Spackman et al. included switching between alternative AEDs and calculated an ICUR of €1,225 per QALY when first-line add-on therapy with zonisamide is followed by second-line lamotrigine compared with first-line add-on therapy with levetiracetam followed by second line lamotrigine. 30 The mean cost per QALY is, therefore, a weighted average of different treatments.
One study examined the cost-utility of retigabine as addon treatment compared to lacosamide as add-on treatment or no add-on treatment in adult patients with refractory epilepsy. 31 It was found that retigabine dominated lacosamide and that the ICUR of retigabine versus no add-on treatment was €16,953 per QALY. A study by Craig et al. 32 compared retigabine with eslicarbazepine acetate, lacosamide, pregabalin, tiagabine, zonisamide, and no treatment (i.e. maintenance therapy). Retigabine was dominated by pregabalin; assuming that pregabalin had been tried but failed, retigabine was dominated by tiagabine. However, assuming that both pregabalin and tiagabine had been tried and failed, retigabine had an ICUR of €23,294 per QALY gained.
Frew et al. 33 examined the cost-effectiveness of newer drugs (i.e., lamotrigine, gabapentin, topiramate, and oxcarbazepine) as add-on therapy for children with focal epilepsies in which they compared the add-on treatment with the situation before the newer AED. They concluded that if there is a willingness to pay £150,000 per QALY, the probability of any of the newer AEDs being cost-effective is <50%. Gharibnaseri et al. 34 examined the cost-effectiveness of adding on new AEDs to conventional regimens in an attempt to control intractable seizures in children. In this study, newer AEDs (i.e., gabapentin, levetiracetam, lamotrigine, oxcarbazepine, topiramate, vigabatrin, and zonisamide) compared with older AED; it was concluded that gabapentin, levetiracetam, and zonisamide were dominated by older AED. Lamotrigine, oxcarbazepine, topiramate, and vigabatrin were argued to be cost-effective treatments with ICERs of, respectively, €1,286, €1,551, €4,246, and €8,851 per responder.
AED as add-on treatment for Lennox-Gastaut syndrome
Two articles have compared levetiracetam add-on with standard therapy in the treatment of patients with the Lennox-Gastaut syndrome. 35, 36 Compared with standard therapy, Blais et al. 36 calculated an ICER for levetiracetam of €80 per seizure-free day gained and Suh and Lee 37 calculated an ICUR for levetiracetam of €11,008 per QALY gained.
Two articles compared rufinamide add-on with lamotrigine or with topiramate add-on. 35 , 38 Benedict et al. 35 calculated an ICER for rufinamide add-on of €3,301 per 1% increase in successfully treated patients with a seizure reduction of ≥50%, compared with lamotrigine add-on (topiramate was dominated). Verdian and Yi 38 calculated an ICUR for rufinamide add-on of €30,810 per QALY gained, compared with topiramate add-on (lamotrigine was dominated). Finally, one study compared clobazam with rufinamide, topiramate, and lamotrigine. At 3-month and 2-year follow-ups, clobazam dominated all other treatments compared. 39 
Nonpharmacologic interventions
Epilepsy surgery
Three studies were identified that looked at the costeffectiveness of epilepsy surgery and compared it with Knoester et al. 14 
2007
Epilepsy All models in our study show that carbamazepine-valproic acid is the reference treatment and that there are more effective treatments, but at considerable costs per extra patient treated effectively. 
17
(1)
2007
Epilepsy The economic analysis lends support to lamotrigine being preferred to CBZ in terms of both cost per seizure avoided and cost per QALY gained. With respect to the latter, there would appear to be a high probability that lamotrigine is a cost-effective alternative to carbamazepine at what might reasonably be considered "affordable" (to the NHS) values of the ceiling ratio.
(1) Both topiramate and gabapentin have positive incremental costs and negative incremental QALY gains and are, therefore, dominated by oxcarbazepine and LTG;
(2) Lamotrigine is ruled out on the grounds of extended dominance; (3) The ICER for oxcarbazepine relative to carbamazepine is €9,787.74 per QALY
Marson et al.
17
(2)
2007
(1) Lamotrigine has a positive incremental cost and a negative incremental QALY gain and is, therefore, dominated by topiramate;
(2) Topiramate versus valproic acid:
€1,746.01
Noble et al. 48 
2014
Epilepsy The ENS-led intervention did not lead to a statistically significant benefit in terms of reducing subsequent visits to ED, nor was there any improvement in the secondary measures of patient well-being.
Based on the average costs and QALY difference, the ENS intervention resulted in lower costs but fewer QALYs. This means that it costs an extra €36,475.95 to achieve one extra QALY if the ENS intervention is NOT used.
Oldham et al. 42 
2015
Refractory epilepsy For the 42% of surgical patients who achieved seizure freedom (ILAE class 1), annual follow-up costs were substantially lower than for patients managed medically.
NR
Plumpton et al. 49 
2015
Epilepsy Intervention which encourages patients to make explicit their intentions to take their antiepileptic medications can represent a cost-effective use of NHS resources, being both less costly and more effective and a 95% probability of being cost-effective.
Dominant
Rane et al. 
2003 Generalized epilepsy In generalized seizures, topiramate followed by lamotrigine has the most favorable cost-effectiveness ratio, given currently accepted United Kingdom thresholds.
(1 Epilepsy Topiramate also had the highest probability of being optimal over a wide range of the ceiling ratio. This analysis suggests that topiramate would be the strategy with the highest probability of being cost-effective.
(1) Vigabatrin treatment resulted in higher utility gain at lower cost, i.e., it dominated adjunctive treatment with clobazam, gabapentin or lamotrigine.
(2) Adjunctive treatment with topiramate had an ICER of €13,246.06 /QALY gained compared with vigabatrin.
Simoens et al. 24 
2012
Refractory epilepsy This economic evaluation showed that standard AED therapy plus lacosamide dominated standard AED therapy alone Standard AED therapy plus lacosamide is more effective and less expensive than standard AED therapy alone for 6, 12, 18, and
months
Spackman et al. (1) The ICER of pregabalin therapy per additional seizure-free day is €27.00; continued medical management, all in children with drugrefractory epilepsy. Bowen et al. 40 evaluated three different scenarios, all with a time horizon of 20 years. Each of the analyses found that epilepsy surgery was cost-effective compared with continued medical management in children with drug-refractory epilepsy; the ICERs were €52,961 and €19,079 for two scenarios (starting the model at referral to a regional epilepsy center and a district epilepsy center, respectively). In the case of choosing epilepsy surgery versus continued medical management in children known to be suitable candidates for surgery, the epilepsy surgery was found to be less costly and provided greater clinical benefit (i.e., is a dominant strategy). In addition, Widjaja et al. 41 found that surgical management of pediatric epilepsy was both more expensive and more effective than medical management. Surgery was found to have an ICER of €28,264 for seizure freedom at 1-year follow-up relative to medical treatment, with a positive net monetary benefit 1 year after surgery. The study by Oldham et al., 42 which did not calculate an ICER, found that in 42% of surgical patients who achieved seizure freedom (ILAE class 1), annual follow-up costs were substantially lower than for patients managed medically.
Ketogenic diet (KD)
Two articles were identified that looked at the cost-effectiveness of the ketogenic diet (KD). 43, 44 One study compared the KD with VNS and care as usual (i.e., medication only) and concluded that from an economic viewpoint that neither VNS nor ketogenic diet is a cost-effective option compared to care as usual at 12 months. In the long-term, the probability of VNS being cost-effective increased to 51% at 5 years (at a ceiling ratio of €80,000 per QALY). The probability of KD being cost-effective becomes 63% at 5 years when all patients are treated with the classical KD, without hospitalization during KD initiation. 44 In the other study, the KD was compared to care as usual with a followup of 4 months. It was concluded that the KD reduced seizure frequency but did not improve quality of life resulting in an unfavorable cost per QALY ratio. 43 
Vagus nerve stimulation (VNS)
In addition to the above-mentioned paper looking at the KD versus VNS and care as usual two studies were identified that examined the cost-effectiveness of VNS in children with epilepsy 45 and children with a special form of epilepsy, Lennox-Gastaut syndrome. 46 Both studies compared the periods before and after VNS implantation. Despite calculating an ICER/ICUR, Helmers et al. 45 concluded that adjunctive VNS is a cost-effective therapy for drug-resistant epilepsy among pediatric patients. In addition, the pre-VNS versus post-VNS analysis demonstrated a positive impact of VNS on both clinical and economic outcomes. The study by Majoie et al. 46 demonstrated an ICER of €21 per single seizure. In addition, the authors concluded that the cost in the 6-month postoperative period is €2,876.06 less than the cost in the preoperative period, and that the device will last for approximately 5 years because of the limited lifetime of the batteries. It then has to be replaced by a new one. The authors further calculate, however, that the payback period is 2.3 years, making VNS an attractive treatment modality from an economic point of view.
Self-management interventions
Three studies looked at the cost-effectiveness of selfmanagement interventions in adults with epilepsy. Beretta et al. 47 compared a standard educational plan with usual care only (i.e., medical management). The standardized educational plan, which consisted of 1 hour of counselling patients, was administered on admission and in the same form after 1 month, as a reminder. Despite calculating an ICER/ICUR, the authors conclude that a patient-tailored educational strategy is effective in reducing drug-related problems (particularly drug interactions) in epilepsy patients with chronic comorbidities, without adding significant monetary costs. The study by Noble et al. 48 examined the cost-effectiveness of a self-management program for adults with epilepsy attending the emergency department. An epilepsy nurse specialist intervention program (two oneto-one sessions delivered on an outpatient basis) was compared to care as usual. Based on the average costs and QALY difference, the self-management intervention resulted in lower costs but fewer QALYs. The calculated ICER in this study showed that it costs an extra €36,475.95 to achieve one extra QALY if the new intervention is NOT used. However, authors add that the study was underpowered to detect the hypothesized effect on emergency department use.
Finally, Plumpton et al. 49 conducted an economic evaluation of a behavior-modifying intervention to enhance AED adherence, which consisted of a booklet of self-report measures following a neurology appointment. In this study, the intervention was both less costly and more effective, and therefore dominated care as usual.
Therapeutic drug-monitoring
One study examined the effect of therapeutic drug-monitoring in adult patients with generalized tonic-clonic epilepsy. 50 The intervention group was compared to a care as usual group. The study did not incorporate an ICER/ICUR, but demonstrated a benefit in terms of reduction in number of seizures, number of adverse events, better earning status, and marital status compared with the group who had not undergone the intervention.
Vulnerable groups
Both the ILAE and NICE guidelines identify several vulnerable groups requiring special attention when providing care. These areas are the following: (1) patients with cognitive deficits, (2) elderly patients, and (3) the treatment of (non)convulsive status epilepticus in both children and adults. No economic evaluations were found that focussed specifically on the first two categories, or on the treatment of (non)convulsive status epilepticus in adults.
Lee et al. 51, 52 conducted two studies on the cost-effectiveness of licensed oromucosal midazolam for the treatment of children experiencing acute epileptic seizure. In the first study, licensed oromucosal midazolam was compared to standard care (unlicensed buccal midazolam and rectal diazepam), unlicensed buccal midazolam, and rectal diazepam. The ICUR of licensed oromucosal midazolam appeared to be dominant in all comparisons. 51 In the second study, Lee et al. 52 compared licensed oromucosal midazolam to the same comparators, placing the outcomes in a country-specific context for Scotland, Wales, Germany, Spain, France, Italy, and Switzerland. Again, the ICURs of licensed oromucosal midazolam appeared to be dominant in all comparisons.
Discussion
This review aims to present an overview of published full economic evaluations of all health care interventions for patients with epilepsy. The chosen structure follows a categorization used by the ILAE and NICE, which will also be applied in the first part of this discussion.
It is important to distinguish between studies that have performed a CUA and those that have performed a CEA. In the CUA, outcomes are presented in cost per QALY gain; in CEA, outcomes are presented in cost per clinical outcome measure (e.g., seizure frequency). In most countries, contrary to cost-effectiveness outcomes, willingness to pay (WTP) thresholds are available for QALYs. For example, in the Netherlands, the WTP for a QALY ranges between €20,000 and €80,000. 53 Consequently, if an ICUR is below this threshold, the intervention is considered to be costeffective. For clinical outcomes, it is difficult to decide whether an intervention is cost-effective, as it is often not known how much society is willing to pay for such a unit of effect (e.g., it is not known how much society is willing to pay for 50% seizure reduction). In addition, it is also difficult to estimate the improvement in QALYs given a certain clinical improvement (e.g., mapping the clinical status of a patient to a utility score).
As well as comparability between studies, it is of utmost importance that the evaluations are of high quality because influential decisions (e.g., reimbursement decision) depend on these. Overall, the methodologic quality was acceptable; however, some studies performed significantly worse than others. A study of Wilby et al. 54 examined the quality of economic evaluations in epilepsy to develop an economic model (without a standardized questionnaire) and concluded that there were problems in studies basing conclusions on a small number of trials and using inappropriate assumptions to extrapolate beyond the length of time of the study. A study of Odenoletkova et al. 11 examined the quality of therapeutic education interventions on the development and progression of type 2 diabetes in a similar way (e.g., using the CHEC) and revealed scores similar to those in our study. However, none of their included articles had a perfect score. In contrast, van Steenbergen et al. 55 examined the quality of economic evaluations in major depressive disorder and found that the included studies scored a maximum of only 53% on the CHEC-list, indicating that the quality of the studies was poor. Finally, a study of Udsen et al. 56 examined the quality of economic evaluations within chronic obstructive pulmonary disease and also concluded that the quality of the economic evidence was poor.
AED as monotherapy and AED as add-on treatment
Difficulties arise when comparing studies. The lack of comparability (e.g., due to different scope, different AED being compared, or specific types of epilepsy) in terms of treatments and/or comparators, means it is difficult to draw overall conclusion. One can conclude that, in comparison to other categories, AEDs have been substantially subjected to economic evaluations.
Epilepsy surgery
No study calculated ICURs for epilepsy surgery. Surgery was, however, found to be more effective in all studies, resulting in ICERs ranging from €19,079 to €52,961 for seizure freedom at 1-year follow-up. All studies were conducted in children. In children known to be suitable candidates for surgery, epilepsy surgery was found to be less costly and provided greater clinical benefit (i.e., is a dominant strategy). The lack of cost-utility analyses makes it difficult to use these studies in policy decisions. In addition, there appears to be a knowledge gap in the economic evaluation of epilepsy surgery in adults.
Ketogenic diet (KD)
The KD was shown to be clinically effective, especially in the randomized controlled trial (RCT) of de Kinderen et al. 43 It was concluded that the KD reduced seizure frequency but did not improve quality of life; therefore, unfavorable cost per QALY ratios resulted. One should, however, be aware of the limited follow-up of the RCT (4-month interim analysis).
Vagus nerve stimulation (VNS)
One author calculated an ICUR and concluded that VNS was not a cost-effective option compared to care as usual at 12 months. In the long-term, the probability of VNS being cost-effective increased to 51% at 5 years (at a ceiling ratio of €80.000 per QALY). 44 Two other articles did not calculate an ICUR, but concluded that this was a costeffective therapy for drug-resistant epilepsy among pediatric patients, 45 and an attractive treatment modality from an economic point of view for pediatric patients with Lennox-Gastaut syndrome. 46 Again, the lack of cost-utility analyses makes it difficult to use these studies in policy decisions.
Self-management interventions
Due to the large variability in self-management intervention, it is difficult to draw broad conclusions. One can, however, conclude that the likelihood of a self-management program being cost-effective is totally dependent on, among others, the content and intensity of the intervention.
Therapeutic drug-monitoring
No ICER/ICUR was calculated but a benefit was demonstrated in terms of seizure reduction, better earning status, and marital status. 50 
Vulnerable groups
Although several vulnerable groups can be identified when looking at the population with epilepsy, only two studies could be identified that looked specifically at children who were experiencing acute epileptic seizures. In both of these, licensed oromucosal midazolam dominated standard care (unlicensed buccal midazolam and rectal diazepam). 51, 52 Studies focusing on other vulnerable groups, such as adults or children with epilepsy combined with cognitive deficits or physical handicaps, are lacking.
Conclusions
To the best of our knowledge, this review is the first to examine economic evaluations within epilepsy for all pharmacologic and nonpharmacologic treatment currently available. Two reviewers were used to select and extract the data, multiple databases were used for the identification of articles, and a quality check was performed for all included studies. In addition, the study protocol was published in the International Prospective Register for Systematic Reviews (PROSPERO) database beforehand, and the PRISMA guidelines were followed.
The fact that all included articles differed substantially in methodology hampered the attempt to combine the information regarding various interventions meaningfully. In addition to the difference between model-based and trial-based economic evaluations, there are many parameters of an economic evaluation that can vary widely from one study to the other. Part of this heterogeneity is unavoidable, because of the multiple choices available when defining parameters of economic evaluations (e.g., designs, outcome measures, and patient samples). On the other hand, part of this heterogeneity can be avoided, simply by following standard economic research methods. (e.g., using the same measure of effectiveness, preferably QALYs or using the same comparators). To overcome this problem, NICE adopted a decision-analytical approach in which all available evidence is synthesized into one newly developed economic model. Albeit being labor-intensive, this approach increases the comparability between studies and makes it more feasible to reach overall (reimbursement) decisions. 57 Furthermore, the heterogeneity between the studies may stress the need to define a reference case and to derive consensus on what constitutes "standard optimal care" in terms of best clinical practice that could serve as a comparator for studies in epilepsy in general and what the preferred clinical outcome measure would be (e.g., 50% seizure reduction and seizure-free patients). Differences were not only attributable to economic parameters but also clinical outcome measures varied extensively. A reference case is a set of methodologic choices for a range of items relevant to conducting an economic evaluation that frame the boundaries of the study, such as model horizon, outcome measure(s), resource use, and costing. 58 Similar initiatives have been developed in the field of osteoporosis and osteoarthritis. 58, 59 A previous review on economic evaluations of AEDs in partial epilepsy also concluded that several methodologic issues hampered their comparability. For example, the inclusion of productivity losses or time horizon. 60 They also emphasized that future health economic evaluations would benefit from efficacy studies that compare relevant alternatives, 60 as there is a lack of head-to-head comparisons especially in AED studies.
The present study is likely to have limitations, one being the lack of synthesized effectiveness data. This was, however, not possible given the wide differences between studies. Furthermore, this study included only published articles and did not search for conference proceedings. Hence, the results may be subject to a (minor) time lag. Finally, in this review we did not discriminate between studies that used a broad societal perspective and a narrower or limited societal perspective. Studies claiming to have been conducted from a societal perspective have been identified as societal perspective irrespective of what costs or outcomes were included. However, studies who claimed to use a societal perspective but used a more narrow perspective (i.e., by omitting productivity losses without valid reasons) have been downgraded in their quality score, as some of the quality criteria specifically ask for the relation between the perspective and actual costs/outcomes included (e.g., items 8 and 11 of the CHEC-list and item 6 of the CHEERS checklist).
Recommendations
Results of this study are useful for policy makers or CPG developers. For example, they are likely to be used in the currently to be updated Dutch CPG for epilepsy. One should, however, take care to look at the quality of a study before taking the results for granted. In addition, if one is interested in CPG development, other aspects, such as transferability of results, should be taken into account. Transferability is the extent to which the results of a study hold true for a different population or setting. 61 64 ). Finally, there is apparently only a small number of economic evaluations in certain areas such as vulnerable groups. Future research should aim to identify and fill knowledge gaps in specific areas within the field of epilepsy and economic evaluations. This review highlights the need for a more standardized approach for conducting economic evaluations within the field of epilepsy. One way forward would be the development of a reference case providing a framework for future studies, hopefully resulting in a more transparent and homogeneous way of conducting economic evaluations. In addition, studies examining the mapping of clinical outcome measures to utility scores could provide an additional way of creating more homogeneous and comparable (i.e., to other disease areas) outcomes. For example, De Kinderen et al. 65 have put first efforts in creating a utility function for transforming clinically relevant epilepsy outcome measures into utility estimates.
